ArticleFrontiers in veterinary science2026
The critical role of flow cytometry in diagnosing aberrant T-cell acute lymphoblastic leukemia in a dog: case report.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) with double-negative T-cell phenotype (CD4-/CD8-) represents a rare presentation in dogs requiring flow cytometry for definitive diagnosis. An eight-year-old German Shepherd presented with progressive lethargy, weight loss, and severe cytopenias. Complete blood count (CBC) revealed severe leukocytosis (90,500/μL) with 99% atypical lymphocytes, non-regenerative anemia, and thrombocytopenia. While blood smear examination demonstrated lymphoblastic morphology, flow cytometry was essential to identify the aberrant immunophenotype CD3+/CD4-/CD8-/CD34+, confirming ALL with arrested differentiation at the earliest T-cell stage. Palliative chemotherapy produced minimal response, and the patient died 11 days post-diagnosis. Flow cytometry results were received 5 days post-mortem, highlighting challenges in turnaround time for specialized diagnostics. This case emphasizes that flow cytometry is essential for accurate diagnosis of acute leukemia with aberrant phenotypes and underscores the need for rapid immunophenotyping services to enable timely therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.